KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2005-12-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.BBRC.2005.10.146PMID 16288721
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mode of action of nerve growth factor in PC12 cells

  2008cited by this paper
• Trapping Prion Protein in the Endoplasmic Reticulum Impairs PrPC Maturation and Prevents PrPSc Accumulation*

  2005cited by this paper
• Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells*

  2005cited by this paper
• Biochemical Fingerprints of Prion Infection: Accumulations of Aberrant Full-Length and N-Terminally Truncated PrP Species Are Common Features in Mouse Prion Disease

  2005cited by this paper
• Mammalian prion biology: one century of evolving concepts.

  2004cited by this paper
• Monoclonal antibodies inhibit prion replication and delay the development of prion disease

  2003cited by this paper
• Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains.

  2003cited by this paper
• Approaches to prophylaxis and therapy.

  2003cited by this paper
• Introduction to the transmissible spongiform encephalopathies or prion diseases.

  2003cited by this paper
• Prion Diseases: From Molecular Biology to Intervention Strategies

  2003cited by this paper
• Anti-prion antibodies for prophylaxis following prion exposure in mice.

  2003cited by this paper
• Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes.

  2002cited by this paper
• Mayhem of the multiple mechanisms: modelling neurodegeneration in prion disease

  2002cited by this paper
• Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody

  2001cited by this paper
• Prions: health scare and biological challenge

  2001cited by this paper
• Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

  2001cited by this paper
• Prion diseases of humans and animals: their causes and molecular basis.

  2001cited by this paper
• Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures

  2000cited by this paper
• Porphyrin and phthalocyanine antiscrapie compounds.

  2000cited by this paper
• Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus.

  2000cited by this paper
• Proteasome inhibitors: valuable new tools for cell biologists.

  1998cited by this paper
• Nobel Lecture: Prions

  1998cited by this paper
• Prion protein expression in different species: analysis with a panel of new mAbs.

  1998cited by this paper
• Characterization of Detergent-insoluble Complexes Containing the Cellular Prion Protein and Its Scrapie Isoform*

  1997cited by this paper
• Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein

  1997cited by this paper
• Intracellular immunization: antibody targeting to subcellular compartments.

  1995cited by this paper
• The Genetics and Transgenetics of Human Prion Disease

  1994cited by this paper
• Structural clues to prion replication.

  1994cited by this paper
• Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins.

  1993cited by this paper
• Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells

  1993cited by this paper
• Evidence for synthesis of scrapie prion proteins in the endocytic pathway.

  1992cited by this paper
• Synthesis and trafficking of prion proteins in cultured cells.

  1992cited by this paper
• Expression and targeting of intracellular antibodies in mammalian cells.

  1990cited by this paper
• Further characterization of scrapie replication in PC12 cells.

  1990cited by this paper
• Separation and properties of cellular and scrapie prion proteins.

  1986cited by this paper
• In vitro replication of scrapie agent in a neuronal model: infection of PC12 cells.

  1984cited by this paper
• Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination.

  1984cited by this paper
• Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

  1976cited by this paper

• Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases

  2020cites this paper
• Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders.

  2020cites this paper
• Muskelin Coordinates PrPC Lysosome versus Exosome Targeting and Impacts Prion Disease Progression.

  2018cites this paper
• Recombinant Antibody Fragments for Neurodegenerative Diseases

  2017cites this paper
• TRIM21 and the Function of Antibodies inside Cells.

  2017cites this paper
• Recent Advances with ER Targeted Intrabodies.

  2016cites this paper
• Specific in vivo knockdown of protein function by intrabodies

  2015cites this paper
• Therapeutic application of intrabodies against age-related neurodegenerative disorders.

  2014cites this paper
• Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation information).

  2014cites this paper
• Potential candidate camelid antibodies for the treatment of protein-misfolding diseases.

  2014cites this paper
• Immunotherapeutic approaches in prion disease: progress, challenges and potential directions.

  2013cites this paper
• Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy

  2013cites this paper
• Gene-Based Antibody Strategies for Prion Diseases

  2013cites this paper
• Parkinson's disease.

  2012cites this paper
• Detection and Control of Prion Diseases in Food Animals

  2012cites this paper
• Intrabody-based gene therapeutic strategy

  2012cites this paper
• Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum.

  2012cites this paper
• Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease

  2012cites this paper
• The role of lipid rafts in prion protein biology.

  2011cites this paper
• Single chain antibody fragment production and metabolic engineering of hyaluronic acid in bacillus and escherichia coli

  2011cites this paper
• Intrabody Expression in Mammalian Cells

  2011cites this paper
• Antibody expression and production

  2011cites this paper
• Expressing Intrabodies in Mammalian Cells

  2010cites this paper
• Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides

  2010cites this paper
• PrP-specific camel antibodies with the ability to immunodetect intracellular prion protein.

  2010cites this paper
• Immunotherapy for prion diseases: opportunities and obstacles.

  2010cites this paper
• PrP-specific camel antibodies with the ability to immunodetect intracellular prion protein.

  2010cites this paper
• Prion Disease Therapy: Trials and Tribulations

  2010cites this paper
• Knockdown surface expression of p75 neurotrophin receptor with ER retained intrabody in mammalian cells

  2010cites this paper
• Developing intrabodies for the therapeutic suppression of neurodegenerative pathology

  2009cites this paper
• Therapeutic interventions ameliorating prion disease

  2009cites this paper
• Development of antibody fragments for immunotherapy of prion diseases.

  2009cites this paper
• Oral pravastatin prolongs survival time of scrapie-infected mice.

  2009cites this paper
• Developingintrabodiesfor thetherapeuticsuppressionof neurodegenerativepathology

  2009cites this paper
• 18 Engineered Antibody Fragments as Potential Therapeutics against Misfolded Proteins in Neurodegenerative Diseases

  2009cites this paper
• Combating protein misfolding and aggregation by intracellular antibodies.

  2008cites this paper
• Rna-codierter antikörper

  2008cites this paper
• Targeting prion proteins in neurodegenerative disease

  2008cites this paper
• The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.

  2008cites this paper
• Anticorps codés arn

  2008cites this paper
• Intracellular antibodies (intrabodies) and their therapeutic potential.

  2008cites this paper
• Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.

  2008cites this paper
• Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies

  2007cites this paper
• Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.

  2007cites this paper
• Therapeutic approaches for prion disorders

  2007cites this paper
• Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: Implications for therapeutic use in prion diseases.

  2007cites this paper
• Selective re‐routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrPSc formation

  2007cites this paper
• Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER

  2007cites this paper
• RNA-encoded antibodies

  2007cites this paper
• T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery

  2007cites this paper
• T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery

  2006cites this paper
• Intracellular antibodies: a revolution waiting to happen?

  2006cites this paper
• A systematic review of prion therapeutics in experimental models.

  2006cites this paper